Commentary

Right to Try: Mission accomplished?


 

Dr. Zonder is a professor in the department of oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University in Detroit. He is the leader of the KCI Myeloma and Amyloidosis Team. He is also a member of the Hematology News Editorial Advisory Board. He reported having no relevant financial disclosures.

References

1. Roberts TG Jr. et al. JAMA. 2004 Nov 3;292(17):2130-40.

2. Fukada YK et al. J Clin Oncol. 2014 May 20. doi: 10.1200/jco.2014.32.15_suppl.2552.

3. Jarow JP et al. Ther Innov Regul Sci. 2017 Mar 1;51(2):177-9.

4. Kearns L et al. Ther Innov Regul Sci. 2017 Mar 1;51(2):170-6.

Pages

Recommended Reading

New NIH consortium aims to coordinate pediatric research programs
MDedge Hematology and Oncology
‘Captain of the ship’ doctrine
MDedge Hematology and Oncology
6 ways to reduce liability by improving doc-nurse teams
MDedge Hematology and Oncology
Azar blames PBMs for no drop in prescription prices
MDedge Hematology and Oncology
FDA already balances safety, access to investigational drugs
MDedge Hematology and Oncology
Rural cancer patients report faster care than urban counterparts
MDedge Hematology and Oncology
Do free meals to physicians affect opioid prescribing?
MDedge Hematology and Oncology
Administration eases way for small businesses to buy insurance in bulk
MDedge Hematology and Oncology
Experts debate affordability of myeloma drugs at ASCO
MDedge Hematology and Oncology
HHS’s Azar teases changes to APMs
MDedge Hematology and Oncology